The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
Abstract
Summary: Tumor immunosurveillance relies on cognate immune effectors [lymphocytes and interferon‐γ (IFN‐γ)] and innate immunity [natural killer (NK) cells, natural killer group 2, member D (NKG2D) ligands, perforin/granzyme, and tumor necrosis factor‐related apoptosis‐inducing ligand]. In parallel, tumor cells promote the expansion of CD4+CD25+ regulatory T cells (Tregs) that counteract T‐cell‐based anti‐tumor immunity. Moreover, accumulating evidence points to a critical role for Tregs in dampening NK cell immune responses. This review summarizes the findings showing that Tregs suppress NK cell effector functions in vitro and in vivo, i.e. homeostatic proliferation, cytotoxicity, and interleukin‐12‐mediated IFN‐γ production. The molecular mechanism involve selective expression of membrane‐bound transforming growth factor‐β on Tregs, which downregulate NKG2D expression on NK cells in vitro and in vivo. The regulatory events dictating NK cell suppression by Tregs have been studied and are discussed. The pathological relevance of the Treg–NK cell interaction has been brought up in tumor models and in patients with cancer. Consequently, inhibition of Tregs through pharmacological interventions should be considered during NK‐cell‐based immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
Sakaguchi, S. (2000) · Cell · doi:10.1016/s0092-8674(00)80856-9 · Cited by 1,815
Making sense of latent TGFβ activation
Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003) · Journal of Cell Science · doi:10.1242/jcs.00229 · Cited by 1,628
Nakamura, K., Kitani, A., & Strober, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.629 · Cited by 1,594
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,568
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Self-citationImai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo
Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M. F., Lawler, J., Hynes, R. O., Boivin, G. P., & Bouck, N. (1998) · Cell · doi:10.1016/s0092-8674(00)81460-9 · Cited by 1,174
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
Morse, M. A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T. M., Valente, N., Shreeniwas, R., Sutton, M. A., Delcayre, A., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-9 · Cited by 1,120
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083 · cited 1×
“Conversely, ectopic expression of Rae1, a mouse NKG2D ligand, promotes NK-cell-mediated rejection of tumors (22, 23).”
BackgroundOnizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Self-citationLutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G. A., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 891
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Self-citationDirect Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells
Yamazaki, S., Iyoda, T., Tarbell, K., Olson, K., Velinzon, K., Inaba, K., & Steinman, R. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030422 · Cited by 865
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Self-citationHomeostasis and anergy of CD4+CD25+ suppressor T cells in vivo
Gavin, M. A., Clarke, S. R., Negrou, E., Gallegos, A., & Rudensky, A. (2002) · Nature Immunology · doi:10.1038/ni743 · Cited by 640
Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1692 · Cited by 634
Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., & Strober, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.834 · Cited by 630
Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
Unravelling natural killer cell function: triggering and inhibitory human NK receptors
Moretta, L., & Moretta, A. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600019 · Cited by 615
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 549
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484
Almeida, A. R. M., Legrand, N., Papiernik, M., & Freitas, A. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4850 · Cited by 468
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
In vivo natural killer cell activities revealed by natural killer cell-deficient mice
Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L., & Yokoyama, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050588297 · Cited by 424
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Interplay of natural killer cells and their receptors with the adaptive immune response
Raulet, D. H. (2004) · Nature Immunology · doi:10.1038/ni1114 · Cited by 413
A novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
Self-citationDifferential antitumor immunity mediated by NKT cell subsets in vivo
Crowe, N. Y., Coquet, J. M., Berzins, S. P., Kyparissoudis, K., Keating, R., Pellicci, D. G., Hayakawa, Y., Godfrey, D. I., & Smyth, M. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050953 · Cited by 392
Natural killer cell receptor signaling
Lanier, L. L. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00039-6 · Cited by 385
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Autoreactive T Cells in Healthy Individuals
Danke, N. A., Koelle, D. M., Yee, C., Beheray, S., & Kwok, W. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5967 · Cited by 377
Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422206 · Cited by 330
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O’Reilly, R. J., Dupont, B., & Vyas, Y. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6891 · Cited by 324
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T. A., & Tagaya, Y. (2005) · Blood · doi:10.1182/blood-2003-12-4187 · Cited by 275
Pharmacology of imatinib (STI571)
Buchdunger, E., O'Reilley, T., & Wood, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80600-1 · Cited by 269
Carrington, M., Wang, S., Martin, M. P., Gao, X., Schiffman, M., Cheng, J., Herrero, R., Rodriguez, A. C., Kurman, R., Mortel, R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042158 · Cited by 231
Oida, T., Zhang, X., Goto, M., Hachimura, S., Totsuka, M., Kaminogawa, S., & Weiner, H. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2516 · Cited by 228
Trzonkowski, P., Szmit, E., Myśliwska, J., Dobyszuk, A., & Myśliwski, A. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.04.003 · Cited by 223
A proportion of patients with lymphoma may harbor mutations of the perforin gene
Clementi, R. (2005) · Blood · doi:10.1182/blood-2004-04-1477 · Cited by 188
Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells
Screpanti, V., Wallin, R. P. A., Grandien, A., & Ljunggren, H.-G. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.033 · Cited by 172
The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect.
Roder, J., Lohmann‐Matthes, M., Domzig, W., et al. (1979) · PubMed · Cited by 166
Hayashi, T., Imai, K., Morishita, Y., Hayashi, I., Kusunoki, Y., & Nakachi, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2776 · Cited by 159
Dasgupta, S., Bhattacharya-Chatterjee, M., O’Malley, B. W., & Chatterjee, S. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5541 · Cited by 158
Thornton, C. A., Upham, J. W., Wikström, M. E., Holt, B. J., White, G., Sharp, M., Sly, P. D., & Holt, P. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3084 · Cited by 148
Trinchieri, G. (1995) · Seminars in Immunology · doi:10.1006/smim.1995.0012 · Cited by 142
Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050707 · Cited by 125
Eidenschenk, C., Dunne, J., Jouanguy, E., Fourlinnie, C., Gineau, L., Bacq, D., McMahon, C., Smith, O. P., Casanova, J., Abel, L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503269 · Cited by 124
Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., Ikarashi, Y., Wakasugi, H., Nakayama, T., Taniguchi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503852102 · Cited by 110
Spontaneous and induced primary oncogenesis in natural killer (nk)‐cell‐deficient beige mutant mice
Haliotis, T. P., Ball, J. K., Dexter, D. F., & Roder, J. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910350414 · Cited by 62
Amino Acid Requirements for Formation of the TGF-β-Latent TGF-β Binding Protein Complexes
Chen, Y., Ali, T., Todorović, V., O’Leary, J. M., Downing, A. K., & Rifkin, D. B. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.10.039 · Cited by 59
Perspectives on cancer immuno‐epidemiology
Nakachi, K., Hayashi, T., Imai, K., & Kusunoki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03178.x · Cited by 53
Activating Ly-49 NK Receptors: Central Role in Cytokine and Chemokine Production
Ortaldo, J. R., Bere, E. W., Hodge, D. L., & Young, H. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4994 · Cited by 48
BCR/ABL Promotes Dendritic Cell–Mediated Natural Killer Cell Activation
Terme, M., Borg, C., Guilhot, F., Masurier, C., Flament, C., Wagner, E. F., Caillat‐Zucman, S., Bernheim, A., Turhan, A. G., Caignard, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2675 · Cited by 46
Self-citationCebo, C., Rocha, S. D., Wittnebel, S., Turhan, A. G., Jalil, A., Caillat‐Zucman, S., Bourhis, J. H., Chouaı̈b, S., & Caignard, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.864 · Cited by 41
Nakajima, T., Mizushima, N., & Kanai, K. (1987) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039215 · Cited by 41
Malignant neoplasms in registered cases of primary immunodeficiency syndrome.
Kobayashi, N. (1985) · PubMed · Cited by 19
Natural Killer Cell Receptor Signaling Pathway in Mammals
Vely, F., & Vivier, É. (2005) · Science s STKE · doi:10.1126/stke.2922005cm7 · Cited by 9
Cited by
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
The role of inflammation in the pathology of preeclampsia
Harmon, A. C., Cornelius, D. C., Amaral, L. M., Faulkner, J. L., Cunningham, M. W., Wallace, K., & LaMarca, B. (2016) · Clinical Science · doi:10.1042/cs20150702 · Cited by 565
Metadata
- Authors
- Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2006-11-07
- Volume
- 214
- Issue
- 1
- Pages
- 229-238
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2162119603
- Cited by
- 273
- References
- 86
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.